Skip to main content

Advertisement

SpringerLink
Log in

Rebamipide Enemas–New Effective Treatment for Patients with Corticosteroid Dependent or Resistant Ulcerative Colitis

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

In this study we investigated the effect of rebamipide enema in patients with steroid-resistant and/or dependent ulcerative colitis. Rebamipide enemas were administered twice daily for a 12-week period; this treatment was further continued longer in patients who requested this. Disease activity index as reflecting the clinical condition and endoscopic index with histological grading were determined before and after the treatment period. Nine of 11 (81.8%) patients on 12-week treatment with rebamipide approved and were classified as colitis in remission. Moreover, seven of 11 patients requested long-term medication, the longest medication term being 80 weeks. These results medicated that rebamipide enemas may be effective in patients with steroid-resistant and/or dependent ulcerative colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629, 1987

    Google Scholar 

  2. Sninsky CA, Cort DH, Shanaban F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo SK, Targan SR, Cerda JJ: Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A Multicenter study [see comments]. Ann Intern Med 115:350–355, 1991

    Google Scholar 

  3. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M: Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 88:1188–1197

  4. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S: Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 40:296–304, 1995

    Article  PubMed  Google Scholar 

  5. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF: A trial of zileuton versus mesalamine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group for Ulcerative Colitis. Gastroenterology 112:718–724, 1997

    Article  PubMed  Google Scholar 

  6. Hanauer S, Sninsky C, Robinson M, Powers B, McHattie J, Mayle J: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 124:204–211, 1996

    PubMed  Google Scholar 

  7. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G: Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 13:373–379, 1999

    Article  PubMed  Google Scholar 

  8. Faubion WA Jr, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260, 2001

    Article  PubMed  Google Scholar 

  9. Makiyama K, Takeshima F, Kawasaki H: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 95:1838–1839, 2000

    Article  PubMed  Google Scholar 

  10. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M: Effect of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43:160S–166S, 1998

    PubMed  Google Scholar 

  11. Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M: Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radical Biol Med 18:117–123, 1995

    Article  Google Scholar 

  12. Yoshikawa T, Naito Y, Tanigawa T, Kondo M: Free radical scavenging activity of the novel anti-ulcer agent rebamipide by electron spin resonance. Arzneim-Forsch/Drug Res 43:363–366, 1993

    Google Scholar 

  13. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y: Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608–1616, 2000

    Article  PubMed  Google Scholar 

  14. Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalamine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 7:237–242, 2001

    Article  PubMed  Google Scholar 

  15. Rachmilewitz D on behalf of an international study group: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 298:82–86, 1989

    Google Scholar 

  16. Floren CH, Benoni C, Willen R: Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 22:459–462, 1987

    PubMed  Google Scholar 

  17. Sood A, Midha V, Sood N, Avasthi G: Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 22:79–81, 2003

    PubMed  Google Scholar 

  18. Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, Izawa H, Yamamura M, Amano K, Satomi M, Shimoyama T: Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1:207–211, 1997

    PubMed  Google Scholar 

  19. Rayner CK, McCormack G, Emmanuel AV, Kamm MA: Long-term results of low-dose intravenous cyclosporine for acute severe ulcerative colitis. Aliment Pharmacol Ther 18:303–308, 2003

    Article  PubMed  Google Scholar 

  20. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 8:231–233, 2004

    Google Scholar 

  21. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford R: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis. N Engl J Med 349:350–357, 2003

    Article  PubMed  Google Scholar 

  22. Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 43:90S–98S, 1998

    Article  PubMed  Google Scholar 

  23. Matysiak-Budnik T, de Mascarel A, Abely M, Mayo K, Heyman M, Megraud F: Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter fells. Scand J Gastroenterol 35:470–475, 2000

    Article  PubMed  Google Scholar 

  24. Matysiak-Budnik T, Thomas-Collignon A, Megraud F, Heyman M: Alteration of epithelial permeability by Helicobacter and IL-1β in vitro: protective effect of rebamipide. Dig Dis Sci 46:1558–1566, 2001

    Article  PubMed  Google Scholar 

  25. Tarnawski A, Chai J, Pai R, Chiou SK: Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 49:202–209, 2004

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Aichi Medical University School of Medicine, 21 Yazako, Nagokute-cho, Aichi-Gun, Aichi, 480-1195, Japan

    Mitsuki Miyata MD, Kunio Kasugai MD, Tetsuya Ishikawa MD, Shinichi Kakumu MD, Masafumi Onishi & Takeshi Mori PhD

Authors
  1. Mitsuki Miyata MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kunio Kasugai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Ishikawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinichi Kakumu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masafumi Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Mori PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuki Miyata MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyata, M., Kasugai, K., Ishikawa, T. et al. Rebamipide Enemas–New Effective Treatment for Patients with Corticosteroid Dependent or Resistant Ulcerative Colitis. Dig Dis Sci 50 (Suppl 1), S119–S123 (2005). https://doi.org/10.1007/s10620-005-2816-1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-005-2816-1

Key Words

Search

Navigation